The Microcap Newsletter
  • Deal Tables
  • News
  • Events
    • The Microcap Conference
    • The SPAC Conference
    • The Reg A Conference
    • The Venture Debt Conference
    • The DTC Healthcare Conference
    • The Healthcare Services
      Investment Conference
  • Free Sign Up
  • Register for The Microcap Conference
Free Sign Up
Attend The Microcap Conference
No Result
View All Result
The Microcap Newsletter
  • Deal Tables
  • News
  • Events
    • The Microcap Conference
    • The SPAC Conference
    • The Reg A Conference
    • The Venture Debt Conference
    • The DTC Healthcare Conference
    • The Healthcare Services
      Investment Conference
  • Free Sign Up
  • Register for The Microcap Conference
Free Sign Up
Attend The Microcap Conference
No Result
View All Result
The Microcap Newsletter
No Result
View All Result

Microcap IPOs Slow to a Halt with an Eye on AI for the Future

May 1, 2023

After an initial second-quarter surge, microcap IPOs slowed nearly to a halt this week.

While larger IPOs dominate the calendar for the first time since early March, advancements in artificial intelligence (AI) are expected to fuel the microcap IPO market in the upcoming months.

Renaissance Capital reports the percentage of US IPOs referencing AI in prospectuses has grown steadily over the past six years, with a 54% jump year-to-date.

The banking crisis delayed IPO timelines, and SEC Chair Gensler’s controversial proposals could impact microcap stock trades.

Historically, the increasing number of AI and technology-based microcap IPOs could outperform other markets as interest rates rise, creating an environment for potential gains.

Parallel Luxury Filing

Cheetah Net Supply Chain Service (CTNT) announced terms for its IPO today and intends to raise $10 million. The company would command a market value of $93 million. Founded in 2016 and based in the United States, Cheetah Net Supply Chain Service sells parallel import luxury cars in China and the U.S. The company booked $55 million in sales for the year ended Dec. 31, 2022. The joint bookrunners on the deal are Pacific Century Securities and Maxim Group.

Cancer Detection and Technology

MDNA Life Sciences (MDLS) has an estimated IPO date of May 3 and seeks to raise over $13 million at a nearly $52 million market cap. Founded in 2002 and based in the United States, the company develops genetic tests to help guide the treatment of cancer and endometriosis using proprietary mitomic technology to detect cancer earlier, less invasively, and more accurately than traditional methods. MDNA booked $3 million in revenue for the year ended June 30, 2022.  EF Hutton is the sole bookrunner on the deal.

Recent Posts

Ten Microcap Companies Charged with Reg A Violations

Ten Microcap Companies Charged with Reg A Violations

May 22, 2023
Microcap IPO Surge Continues Amidst Silicon Valley Din

Microcap IPO Flow Slows to a Trickle

May 22, 2023
Bi-Monthly Report on SEC Oversight of Penny Stock Violations

Pyramids and a Ponzi, Bank Fraud, Mask Fraud & General Theft

May 22, 2023
DealFlow Events logo

PO Box 122
Syosset, NY 11791
(516) 876-8006
team@dealflowevents.com

Subscribe to our free newsletter

Stay informed on the latest weekly Microcap news.

SIGN UP

© DealFlow Financial Products, Inc. (d/b/a DealFlow Events). All rights reserved. DealFlow Events™ and The Microcap Conference™ and The Microcap Newsletter™ are trademarks of DealFlow Financial Products, Inc.

  • Deal Tables
  • News
  • Events
    • The Microcap Conference
    • The SPAC Conference
    • The Reg A Conference
    • The Venture Debt Conference
    • The DTC Healthcare Conference
    • The Healthcare Services
      Investment Conference
  • Free Sign Up
  • Register for The Microcap Conference